Literature DB >> 27061275

Clinical, muscle pathological, and genetic features of Japanese facioscapulohumeral muscular dystrophy 2 (FSHD2) patients with SMCHD1 mutations.

Kohei Hamanaka1, Kanako Goto2, Mami Arai2, Koji Nagao3, Chikashi Obuse3, Satoru Noguchi4, Yukiko K Hayashi5, Satomi Mitsuhashi6, Ichizo Nishino4.   

Abstract

Facioscapulohumeral muscular dystrophy 2 (FSHD2) is a genetic muscular disorder characterized by DNA hypomethylation on the 4q-subtelomeric macrosatellite repeat array, D4Z4. FSHD2 is caused by heterozygous mutations in the gene encoding structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1). Because there has been no study on FSHD2 in Asian populations, it is not known whether this disease mechanism is widely seen. To identify FSHD2 patients with SMCHD1 mutations in the Japanese population, bisulfite pyrosequencing was used to measure DNA methylation on the D4Z4 repeat array, and in patients with DNA hypomethylation, the SMCHD1 gene was sequenced by the Sanger method. Twenty patients with D4Z4 hypomethylation were identified. Of these, 13 patients from 11 unrelated families had ten novel and one reported SMCHD1 mutations: four splice-site, two nonsense, two in-frame deletion, two out-of-frame deletion, and one missense mutations. One of the splice-site mutations was homozygous in the single patient identified with this. In summary, we identified novel SMCHD1 mutations in a Japanese cohort of FSHD2 patients, confirming the presence of this disease in a wider population than previously known.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  D4Z4; DNA methylation; Facioscapulohumeral muscular dystrophy 2; Pyrosequence; Structural maintenance of chromosomes flexible hinge domain containing 1

Mesh:

Substances:

Year:  2016        PMID: 27061275     DOI: 10.1016/j.nmd.2016.03.001

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  5 in total

1.  SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain.

Authors:  Richard J L F Lemmers; Nienke van der Stoep; Patrick J van der Vliet; Steven A Moore; David San Leon Granado; Katherine Johnson; Ana Topf; Volker Straub; Teresinha Evangelista; Tahseen Mozaffar; Virginia Kimonis; Natalie D Shaw; Rita Selvatici; Alessandra Ferlini; Nicol Voermans; Baziel van Engelen; Sabrina Sacconi; Rabi Tawil; Meindert Lamers; Silvère M van der Maarel
Journal:  J Med Genet       Date:  2019-06-26       Impact factor: 6.318

2.  Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Ana Blatnik; Judit Balog; Janez Zidar; Don Henderson; Rianne Goselink; Stephen J Tapscott; Nicol C Voermans; Rabi Tawil; George W A M Padberg; Baziel Gm van Engelen; Silvère M van der Maarel
Journal:  J Med Genet       Date:  2021-01-12       Impact factor: 6.318

Review 3.  A pediatric case report and literature review of facioscapulohumeral muscular dystrophy type1.

Authors:  Ting Xiao; Haiyan Yang; Siyi Gan; Liwen Wu
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

4.  Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy.

Authors:  Kohei Hamanaka; Darina Šikrová; Satomi Mitsuhashi; Hiroki Masuda; Yukari Sekiguchi; Atsuhiko Sugiyama; Kazumoto Shibuya; Richard J L F Lemmers; Remko Goossens; Megumu Ogawa; Koji Nagao; Chikashi Obuse; Satoru Noguchi; Yukiko K Hayashi; Satoshi Kuwabara; Judit Balog; Ichizo Nishino; Silvère M van der Maarel
Journal:  Neurology       Date:  2020-05-28       Impact factor: 11.800

Review 5.  Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.

Authors:  Anna Greco; Remko Goossens; Baziel van Engelen; Silvère M van der Maarel
Journal:  Clin Genet       Date:  2020-03-04       Impact factor: 4.438

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.